Photobiomodulation (PBM / Red Light Therapy) for Alzheimer's Disease
Also known as: PBM, Low-level light therapy, LLLT, Red light therapy, Near-infrared therapy
PBM addresses mitochondrial dysfunction and neuroinflammation — two key pathological features of Alzheimer's — while promoting BDNF-driven neuroplasticity.
Mechanism of Action
In Alzheimer's, PBM stimulates mitochondrial function in neurons and astrocytes, reduces amyloid-beta-induced oxidative stress, inhibits microglial-driven neuroinflammation, and promotes BDNF expression for synaptic plasticity. Improved cerebral blood flow may enhance clearance of metabolic waste through the glymphatic system.
General mechanism: Red/NIR photon absorption by cytochrome c oxidase (Complex IV). Boosts ATP, reduces ROS, activates NF-κB/MAPK survival signaling, induces BDNF.
Current Evidence
Small clinical studies show cognitive improvement with transcranial PBM in Alzheimer's patients. The mechanism is consistent with addressing multiple AD pathological features. Larger controlled trials are needed.
Clinical Status: Small clinical studies positive. Phase II trials underway. Home-use devices available.
Safety Profile
Excellent safety. No significant adverse effects. Non-invasive. Eye protection needed for direct light exposure. Home-use devices widely available.
Key Research Questions
- Can PBM enhance glymphatic clearance of amyloid during sleep?
- Does PBM combination with anti-amyloid therapy provide additive benefit?